Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries AbbVie (NY: ABBV ) 191.26 -2.25 (-1.16%) Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about AbbVie < Previous 1 2 3 4 5 6 7 8 9 ... 67 68 Next > Behind the Scenes of AbbVie's Latest Options Trends September 24, 2024 Via Benzinga Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years September 20, 2024 KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental... Via Benzinga Exposures Product Safety Spotlight on AbbVie: Analyzing the Surge in Options Activity September 20, 2024 Via Benzinga Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry September 19, 2024 Via Benzinga 2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? September 19, 2024 Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. Via Investor's Business Daily 2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again September 19, 2024 For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again. Via The Motley Fool Topics Stocks Exposures US Equities Is ABBVIE INC Ready to Break Out of Its Range? September 17, 2024 Interesting Technical Analysis finding for ABBVIE INC (NYSE:ABBV) Via Chartmill What the Options Market Tells Us About AbbVie September 11, 2024 Via Benzinga Spotlight on AbbVie: Analyzing the Surge in Options Activity September 09, 2024 Via Benzinga Abbie Inc Stocks Elliott Wave Technical Analysis - Wednesday, September 18, September 18, 2024 Looking for upside into wave {v} as we are trading within the parallel channel where we could eventually seek for support within wave {iv}. Via Talk Markets TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades' September 17, 2024 TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as top trades on CNBC's Halftime Report. Via Benzinga Topics ETFs Can AbbVie Regain Its Status As a Top Dividend Growth Stock? September 16, 2024 The dividend growth powerhouse is turning the corner. Via The Motley Fool Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More September 14, 2024 Financial factors aren't the only things that are worth paying attention to. Via The Motley Fool 3 Stocks to Buy and Hold Forever September 14, 2024 These stocks are built for the long run. Via The Motley Fool Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever September 14, 2024 Their dividends are solid. And their businesses are built for the long run. Via The Motley Fool Peering Into AbbVie's Recent Short Interest September 06, 2024 Via Benzinga Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today September 05, 2024 Via Benzinga Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... Via Talk Markets Topics ETFs Is This Company Still a Strong Buy After Tripling the S&P 500's Returns? September 13, 2024 The stock has been a winner, but there may be better times ahead for buying. Via The Motley Fool Topics Stocks Exposures US Equities UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars September 11, 2024 UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. Via Benzinga Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies September 10, 2024 Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated to education, recovery centers, and outreach initiatives. Via Benzinga 3 Things You Need to Know if You Buy AbbVie Stock Today September 09, 2024 This dynamic big pharma is undergoing a few key changes. Via The Motley Fool 3 No-Brainer Dividend Stocks to Buy in September September 08, 2024 These stocks pay great dividends and could be long-term winners. Via The Motley Fool Earn $1,000 Per Month in Dividends From These 4 Stocks September 07, 2024 A mix of various types of dividend investments. Via The Motley Fool Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration September 05, 2024 The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever September 05, 2024 There is something for everybody in America's $4.5 trillion healthcare market. Via The Motley Fool AbbVie Stock Post Humira is Still an Attractive Stock to Hold September 04, 2024 AbbVie's strategic diversification and strong financial position make it possible to sustain growth despite the perceived “Humira cliff.” Via MarketBeat Topics Intellectual Property Exposures Intellectual Property New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth September 04, 2024 EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 10 Health Care Stocks With Whale Alerts In Today's Session September 03, 2024 Via Benzinga New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth September 04, 2024 From FN Media Group LLC Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 67 68 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.